Vagal Nerve Stimulator for Post-Stroke Hemiparesis
FDA-Approved Indications for VNS
- The FDA approves VNS only for refractory epilepsy and treatment-resistant depression, not for post-stroke rehabilitation or hemiparesis 3, 1
- The American Academy of Neurology indicates that VNS is approved as an adjunctive therapy for patients with refractory epilepsy who have failed to manage their seizures with pharmacologic solutions alone, typically after trying two or more anti-epileptic drugs 1
- The LivaNova VNS device received FDA approval in 1997 specifically as an adjunctive therapy for patients with refractory epilepsy 4
Evidence for VNS in Stroke Rehabilitation
- Current guidelines from the American Heart Association specifically list stroke as an indication for which there is insufficient evidence to support VNS therapy 1
- VNS for stroke rehabilitation is considered experimental because its effectiveness for this indication has not been established, according to the American College of Physicians 1, 2
- While VNS has been investigated for various conditions beyond epilepsy, stroke rehabilitation remains an experimental application, as stated by the National Institute of Neurological Disorders and Stroke 3
Technical Aspects of VNS Implantation
- VNS implantation involves placing helical cuff electrodes on the left cervical vagal trunk connected to an implanted pulse generator in the chest, as described by the American Association of Neurological Surgeons 4
Clinical Decision Algorithm
- The American Academy of Neurology recommends determining if the patient has an FDA-approved indication for VNS, such as refractory epilepsy or treatment-resistant depression 1
- For patients with post-stroke hemiparesis, the American College of Physicians states that this is not an FDA-approved indication and current guidelines classify this as experimental 1, 2